S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC

OncLive® On Air - A podcast by OncLive® On Air

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.

Visit the podcast's native language site